>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

BVX +16.1%, OCN +13.6%, UCTT +10.1%, STM +9.7%, STM +9.7%, TTMI +9.6%, PCMI +8.3%, CAKE +8.1%, CSII+7.1%, PLNT +7%, SFLY +7%, FFIV +6.9%
TER +6.3%, SQNS +6.2%, NOW +5.8%, (also Chairman Paul Barber resigns; CEO Frank Slootman selected as replacement ), PTC +5.6%, VMW +5.6%, QTM +5.3%
BWLD +4.9%, TWTR +4.9%, YNDX +4.7%, BOOT +4.5%, WDC +4.4%, XRS +4.4%, MB +4.2%, BMY +4%, TSLA+3.8%, EGHT +3.7%, BCS +3.7%, ALXN +3.6%
CELG +3.6%, ESV +3.2%, QCOM +3%, IPGP +2.9%, TCK +2.7%, DPS +2.7%, NOV +2.6%, SIRI +2.6%, TPH +2.3%,NXPI +2.1%, EPE +2%, ATNI +2%,
ABX +2%, STO +2%, STO +2%, TPX +2%, CRY +1.8%, SU +1.7%, POT +1.5%, TMO +1.5%, SRPT +1.4%, VALE+1.4%, AEM +1.2%, DOW +1.2%, RTN +1.2%
DLB +1.1%, JBT +1.1%, LAZ +1.1%, VC +1.1%, CDE +1%, EFX +1%, UFI +1%, AET +0.9%, XL +0.8%, SJW +0.8%,HBP +0.7%, COP +0.7%, AG +0.5%

M&A news:

QCOM +2.9% (acquiring NXPI for $110/share)
NXPI +1.9% (to be acquired by Qualcomm (QCOM) for $110/share in cash; also reported earnings)

Select large pharma names showing strength: SNY +1.9%, NVO +1.7%, AZN +1.4%, NVS +1%, SHPG +0.9%

Other news:

PRQR +30.1% (announces that clinical study PQ-010-002 demonstrated that QR-010 restored CFTR function in a cohort of homozygous F508 cystic fibrosis (CF) patients; meets primary endpoint)
VNR +26.8% (made the approximate $15 mln semi-annual interest payment on its 7.875% Senior Notes due 2020; entered into limited waiver and amendment to its reserve-based credit facility)
GALE +6.7% (shareholders approve amendment to effect a reverse stock split at a ratio of not less than 1 for 2 and not greater than 1 for 20)
HCA +4.2% (announces agreement to terminate hospital lease and associated Joint Operating Agreement in Oklahoma)
SCTY +3.6% (on TSLA earnings)
SN +2.3% (gives Q3 production results; oil production of 51,500 Boe/d was at high end of 50K-52K guidance)

Analyst comments: